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OBJECTIVES: Pharmacoeconomic assessment of cefa-
mandole/tobramycin (CT) versus standard therapy (ST)
in the treatment of local appendicular peritonitis (LAP).
Standard therapy was antibacterial drugs routinely used
for treatment of LAP in centers of study. It was allowed
to add metronidazole to both regimes.
METHODS: Clinical outcomes and health resource utili-
zation data were collected from 92 patients enrolled in an
open, comparative, randomized, prospective, multicenter
trial comparing the efficacy and safety of CT versus ST in
the treatment of LAP. A cost-minimization analysis was
performed from the institutional perspective. Costs of
study antibiotics, treatment of failures and adverse events
(AE), and hospitalization were calculated.
RESULTS: The most common regimes in ST were ampi-
cillin (27%), ampicillin 
 oxacillin (11%), penicillin 

gentamicin (9%), penicillin 
 kanamycin (9%). Metron-
idazole was used in five patients in CT and in four pa-
tients in ST. Cure rates were 42 of 44 (95.5%) for CT
and 41 of 45 (91.1%) for ST (p  1.000). Adverse events
(AE) were 12 of 47 (25.5%) for CT and 10 of 45
(22.2%) for ST (p  0.547). Three levels of cost were an-
alyzed: level I  study drug acquisition cost; level II 
level I 
 preparation/administration 
 treatment of AE/
failures 
 hospital bed costs; level III  level II 	 level I.
CONCLUSIONS: ST was cost-effective compared to CT
in the treatment of LAP. The pharmacoeconomic advan-
tage of ST was due to the significantly lower acquisition
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OBJECTIVES: The present study ascertains the annual
direct costs of common psychotropic medications used in
the management of common psychiatric disorders in a
country with limited financial resources.
METHODS: The direct costs of the psychopharmacologi-
cal agents evaluated were antidepressants (tricyclic, SSRI,
and newer antidepressants available); antipsychotics (phe-
nothiazines, butrophenones, and atypical antipsychotics);
benzodiazepines and sedatives. The annual direct costs of
the medications were ascertained from the recent monthly
index for medical specialties (MIMS), from standard
chemists, and from pharmaceutical firms. The statistical
mode or most frequent cost was considered for further
computations. 
RESULTS: Regarding antidepressants, tricyclics were
noted to have the following annual costs (1 US$  Rs.
43): Imipramine Rs. 1130 (US $26.3), amitriptyline Rs.
1460 ($34), dothiepin Rs. 2410 ($56.1), trimipramine
Rs. 2430 ($56.5) and clomipramine Rs. 6130 ($142.6).
Fluoxetine has an annual cost of Rs. 840 ($19.5), mi-
anserin Rs. 2010 ($46.7), amoxapine Rs. 3835 ($89.1),
amineptine Rs. 10,700 ($248.8), and the most expensive,
tianeptine, Rs. 21,000 ($488). The recently introduced
antidepressant sertraline has an annual cost of Rs. 2740
($63.7). Prophylaxis for affective disorders with lithium
therapy would have an annual cost of Rs. 1200 ($27.9).
Regarding antipsychotics, the annual costs of oral medi-
cations of chlorpromazine and haloperidol were the
same, Rs. 2000 ($46.5), long-acting oral penfluridol Rs.
500 ($11.6), and depot long-acting injectable fluphena-
zine decanoate, haloperidol decanoate, and flupenthixol
Rs. 750 ($17.4), Rs. 1500 ($34.9), and Rs. 2100 ($48.8),
respectively. The newer atypical antipsychotics costs
were: resperidone, Rs. 4500 ($104.7) and clozapine Rs.
5500 ($127.9). Benzodiazepines have an annual cost of
$7.5 for diazepam, $3.5 for lorazepam and chlordiazep-
oxide, $2.8 for oxazepam, and $17.6 for alprazolam.
Sleep medications nitrazepam, flurazepam and zopiclone
have an annual cost of $3.3, $8, and $18.8 respectively.
CONCLUSION: The annual costs are amazingly less
than those in Western nations, but nevertheless produce a
significant burden on Indian families, and are a common
reason for poor compliance. Another trend noted above
is that newer antidepressants such as amineptine and
tianeptine, antipsychotics such as resperidone and clozap-
ine, and hypnotics such as zopiclone are much more ex-
pensive than the older medications. Thus, the annual
costs of medications are only likely to increase with time,
enhancing the financial burden of treating these psychiat-
ric disorders.
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Many antidepressant drugs are prescribed by generalist
physicians. However, few details are available concerning
the circumstances in which these drugs are utilized in pri-
mary care settings.
Cost $ (1997 year) CT ST P value
Level I 103.0  41.0 14.9  13.2 0.001
Level II 275.3  118.1 189.9  99.1 0.001
Level III 172.2  96.9 175.5  99.6 0.904
